LEADER 02245nam 2200433 n 450 001 996386106303316 005 20200824121044.0 035 $a(CKB)1000000000602526 035 $a(EEBO)2240872252 035 $a(UnM)99843727e 035 $a(UnM)99843727 035 $a(EXLCZ)991000000000602526 100 $a19910730d1580 uy | 101 0 $aroa 135 $aurbn||||a|bb| 200 03$aLe court leete, et court baron, collect per Iohn Kytchin de Greys Inne vn appre[n]tice en le ley, et les cases et matters necessaries pur seneschals de ceux courts a scier, pur les students de les measons de chauncerie$b[electronic resource] 205 $aOre nouelment imprimee,$bet per laucthor mesme corrigee, ouesq[ue] diuers nouel cases et titles a ceo per luy addes. 210 $a[London] $cIn ędibus Richardi Tottelli$dOctobris quarto. Anno D[omi]ni. 1580. Cum priuilegio ad imprimendum solum 215 $a[8], 216 leaves 300 $aAt foot of title: Cum priuilegio ad imprimendum solum. 300 $aIn two parts. 300 $aA1 is a separate title page, with same imprint, reading: Retourna breuium. Nouelment corrigee, ouesque diuers auters bones retournes, et moultes cases del co[m]menley a ceo addes, for necessarie .. 300 $aAnother issue of STC 15017, originally published in 1580. 300 $aPart 2 reprints STC 20894.4, Returna br[eviu]m, originally published in 1516. Its text is included in STC 15019-15025--STC. 300 $aSignatures: [par.] B-Ee A-G Hā“ (-[par.]1-2 blank?). 300 $aSome print faded and show-through; some pages stained. 300 $aReproduction of the original in the Bodleian Library. 330 $aeebo-0113 606 $aCourts baron and courts leet$vEarly works to 1800 615 0$aCourts baron and courts leet 700 $aKitchin$b John$01004390 801 0$bCu-RivES 801 1$bCu-RivES 801 2$bCStRLIN 801 2$bWaOLN 906 $aBOOK 912 $a996386106303316 996 $aLe court leete, et court baron, collect per Iohn Kytchin de Greys Inne vn appretice en le ley, et les cases et matters necessaries pur seneschals de ceux courts a scier, pur les students de les measons de chauncerie$92307098 997 $aUNISA LEADER 03812nam 22006854a 450 001 9910777636203321 005 20230828220844.0 010 $a0-19-756195-0 010 $a1-280-83783-7 010 $a0-19-974906-X 010 $a1-4294-0273-3 035 $a(CKB)1000000000465632 035 $a(OCoLC)71794280 035 $a(CaPaEBR)ebrary10375127 035 $a(SSID)ssj0000154401 035 $a(PQKBManifestationID)11149353 035 $a(PQKBTitleCode)TC0000154401 035 $a(PQKBWorkID)10427223 035 $a(PQKB)11512995 035 $a(MiAaPQ)EBC3053633 035 $a(StDuBDS)EDZ0002341412 035 $a(Au-PeEL)EBL3053633 035 $a(CaPaEBR)ebr10375127 035 $a(CaONFJC)MIL83783 035 $a(EXLCZ)991000000000465632 100 $a20050504d2006 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aFibrinolytic and antithrombotic therapy$b[electronic resource] $etheory, practice, and management /$fRichard C. Becker, Frederick A. Spencer 205 $a2nd ed. 210 $aOxford ;$aNew York $cOxford University Press$d2006 215 $a1 online resource (421 p.) 225 1 $aOxford scholarship online 300 $aPreviously issued in print: 2006. 311 $a0-19-515564-5 320 $aIncludes bibliographical references and index. 327 $aHistorical perspectives in hemostasis, coagulation and fibrinolysis -- Vascular biology, thromboresistance and inflammation -- Atherosclerosis and arterial thrombosis -- Venous thromboembolism -- Cardiac chamber, aortic and valvular thromboembolism -- Fibrinolytic agents -- Aspirin -- Clopidogrel -- Platelet Glycoprotein IIb/IIIa receptor antagonists -- Aggrenox and cilostazol -- Novel platelet antagonists -- 327 $aCombination pharmacotherapy -- Facilitated percutaneous coronary intervention -- Thrombin-directed therapy -- Factor Xa inhibitors -- Direct thrombin inhibitors -- Novel anticoagulants -- Acute coronary syndromes -- Peripheral vascular disease and stroke -- Valvular heart disease and atrial fibrillation -- Plaque-stabilizing therapies -- 327 $aVenous thromboembolism prophylaxis -- Venous thromboembolism treatment -- Fundamentals and patient evaluation -- Platelet antagonists -- Anticoagulants -- Anticoagulation clinics and self-testing -- Platelet antagonists -- Anticoagulants -- Fibrinolytic agents. 330 8 $aThrombotic disorders of the circulatory system represent the leading cause of morbidity, mortality, and health care expenditure in the United States. The Second Edition of Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the managment of thrombotic disorders for all clinicians involved in the care of patients with these disorders. It provides not only vital conceptual information on fibrinolytic and antithrombotic therapy, but also the means to apply it to everyday decision making and patient care. Focusing on management guidelines and critical pathways, the text stresses practicality and usability. It will be a valuable resource for the wide range of clinicians involved in the care of patients with these disorders. 410 0$aOxford scholarship online. 606 $aThrombolytic therapy 606 $aFibrinolytic agents 606 $aThrombosis$xTreatment 615 0$aThrombolytic therapy. 615 0$aFibrinolytic agents. 615 0$aThrombosis$xTreatment. 676 $a616.1/3506 700 $aBecker$b Richard C$044739 701 $aSpencer$b Fredrick A.$cMD.$01563240 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910777636203321 996 $aFibrinolytic and antithrombotic therapy$93831484 997 $aUNINA